順藥 (6535.TWO)

234.00 +7.00 (+3.08%) 收市：01:30PM CST

順藥

No. 3-2, Park Street
4th Floor Nangang District
Taipei 11503
Taiwan
886 2 2655 7918
https://www.lumosa.com.tw

版塊: Healthcare
行業: Biotechnology
全職員工: 47

高階主管

名稱	頭銜	支付	行使價	出生年份
Li Fang Pan	Chief Financial Officer and Manager of the Administrative Office	無	無	無
Pei-Jiun Chen	Chief Operating Officer	無	無	無
Jia Qi Yang	Financial Officer, Accounting Officer & Acting Spokesperson	無	無	無
Todd Ban	Head of Business Development Division	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

公司管治

截至 無 止，順藥 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。